相关实验视频

Updated: Jun 30, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

在帕金森病中通过多巴胺调节在门中持续的异常活动:静止状态神经成像元分析

Danyan Rong¹, Chuan-Peng Hu², Jiaying Yang³

¹Department of Neurology, The Affiliated Brain Hospital of Nanjing Medical University, No.264, Guangzhou Road, Gulou District, Nanjing, Jiangsu 210029, China.

Brain research bulletin

|March 20, 2024

概括

口服抗帕金森症药物会影响大脑活化,特别是在右骨中,这可能作为在帕金森病 (PD) 中治疗疗效的成像生物标志物. 这项研究分析了78项神经成像研究.

科学领域:

神经成像是一种神经成像.
运动障碍运动障碍
药理学药理学是指药理学的学科.

背景情况:

帕金森病 (PD) 涉及异常的大脑活动,特别是当患者不服用药物时 (PD-OFF状态).
了解药物 (PD-ON状态) 如何改变大脑功能对于有效治疗至关重要.
休息状态激活模式和功能连接提供了对PD病理生理学的见解.

研究的目的:

在接受口服药物治疗的PD患者中识别大脑区域的静止状态激活发生变化.
使用元分析技术研究这些大脑区域的功能连接.
探索特定大脑区域作为治疗反应的成像生物标志物的潜力.

主要方法:

在PubMed和Web of Science的系统文献搜索中,发现了78项相关的神经成像研究.
使用了基于坐标的元分析和功能元分析连接建模 (MACM).
激活概率估计 (ALE) 算法用于数据分析.

主要成果:

在与PD-OFF和PD-ON状态进行比较时,在右门和左下叶中观察到大脑激活的显著变化.
与健康对照组 (HCs) 相比,PD-OFF状态显示了包括右门和丘脑在内的区域的激活增加.
与HC相比,PD-ON状态显示了中圈和右尾骨等区域的激活发生变化,右骨是关键的协同激活区域.

结论:

面,特别是右侧,始终参与与PD中药物效应相关的局部大脑区域激活和协同激活网络.
这些发现表明,布塔门的潜力作为一个特定的成像生物标志物,用于监测口服抗帕金森治疗的疗效.
进一步的研究可以验证门在跟踪治疗反应和疾病进展方面的作用.

关键词:

进行元分析分析.与口服抗帕金森药物相关的激活大脑区域.帕金森病是帕金森氏症的一种疾病.休息状态功能神经成像.

更多相关视频

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

Primary Culture of Mouse Dopaminergic Neurons

Primary Culture of Mouse Dopaminergic Neurons

Published on: September 8, 2014

相关概念视频

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Drugs Affecting Neurotransmitter Synthesis

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...